Ashwagandha Can Prevent Covid-19 Virus Infection, Research Says

IIT Delhi and Japan's AIST Research Says

COVID-19 Updates
  • World 161,472,341
    Confirmed: 161,472,341
    Active: 17,829,134
    Recovered: 140,292,022
    Death: 3,351,185
  • USA 33,589,578
    Confirmed: 33,589,578
    Active: 6,370,885
    Recovered: 26,620,848
    Death: 597,845
  • India 23,943,878
    Confirmed: 23,943,878
    Active: 3,699,515
    Recovered: 19,983,310
    Death: 261,053
  • Brazil 15,361,686
    Confirmed: 15,361,686
    Active: 1,009,213
    Recovered: 13,924,217
    Death: 428,256
  • Turkey 5,072,462
    Confirmed: 5,072,462
    Active: 227,350
    Recovered: 4,801,291
    Death: 43,821
  • Russia 4,913,439
    Confirmed: 4,913,439
    Active: 270,838
    Recovered: 4,527,878
    Death: 114,723
  • UK 4,444,631
    Confirmed: 4,444,631
    Active: 58,682
    Recovered: 4,258,298
    Death: 127,651
  • Italy 4,139,160
    Confirmed: 4,139,160
    Active: 346,008
    Recovered: 3,669,407
    Death: 123,745
  • Germany 3,569,249
    Confirmed: 3,569,249
    Active: 242,760
    Recovered: 3,240,300
    Death: 86,189
  • Pakistan 870,703
    Confirmed: 870,703
    Active: 75,052
    Recovered: 776,315
    Death: 19,336
  • China 90,808
    Confirmed: 90,808
    Active: 291
    Recovered: 85,881
    Death: 4,636

NEW DELHI: Ayurvedic herb Ashwagandha can be an effective therapeutic and preventive drug against the COVID-19 infection, a collaborative research by IIT-Delhi and Japan’s National Institute of Advanced Industrial Science and Technology (AIST) has found. The natural compounds from Ashwagandha and Propolis have the potential to be an effective novel coronavirus preventive drug, according to the research team.

“The researchers targeted the main SARS-CoV-2’s enzyme for splitting proteins, known as the main protease (Mpro), that plays a key role in mediating viral replication. This is an attractive drug target for this virus, and as humans don’t naturally have this enzyme, compounds that target Mpro are likely to have low toxicity,” said D Sundar, head of the Delhi Indian Institute of Technology’s Biotechnology department.

“The findings may not only connect to save time and cost required for screening for anti-COVID-19 drugs, but may also offer some preventive and therapeutic value for the management of fatal COVID-19 pandemic, and hence, warrant prioritized validation in the laboratory and clinical tests,” he said.


Get real time updates directly on you device, subscribe now.

Leave A Reply

Your email address will not be published.